Co-Authors
This is a "connection" page, showing publications co-authored by Lee Fairlie and Nomathemba Chandiwana.
Connection Strength
1,175
-
High loss to follow-up of children on antiretroviral treatment in a primary care HIV clinic in Johannesburg, South Africa. Medicine (Baltimore). 2018 Jul; 97(29):e10901.
Score: 0,635
-
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz. AIDS. 2021 12 15; 35(Suppl 2):S117-S125.
Score: 0,202
-
Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa. AIDS. 2021 02 02; 35(2):205-211.
Score: 0,190
-
Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens. Open Forum Infect Dis. 2024 Mar; 11(3):ofae007.
Score: 0,058
-
Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020 10; 7(10):e666-e676.
Score: 0,046
-
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019 08 29; 381(9):803-815.
Score: 0,043